Neurology - STAT

Pharmalot By Ed Silverman

Expert panel votes unanimously that Biogen Alzheimer’s drug doesn’t offer patient benefits

STAT Summit By Elizabeth Cooney

‘Aduhelm left room’: Lilly CEO eyes competition with Biogen Alzheimer’s drug

Pharmalot By Ed Silverman

Poll: Most neurologists and primary care doctors disagree with FDA’s approval of Alzheimer’s drug

Pharmalot By Ed Silverman

Will FDA quickly review a Lilly drug to alleviate cost concerns for Alzheimer’s treatments?

Pharmalot By Ed Silverman

‘A litany of flaws’: Advocacy group urges HHS to boot FDA officials over Alzheimer’s drug approval

Biotech By Nicholas Florko

Advocates blast the FDA for not moving as fast on ALS as on Alzheimer’s

Biotech By Felice J. Freyer — Boston Globe

What’s next for the new Alzheimer’s drug? Lots of thorny issues ahead

Health By Erika Check Hayden

The parents hoped an existing drug might keep their kids from having seizures. Then they saw the price

Pharmalot By Ed Silverman

Biogen’s Alzheimer’s drug may only be cost effective at $2,500 a year

Pharmalot By Ed Silverman

Biogen to expand access to its ALS drug, but move may come too late for some patients

Health By Sara Reardon

Covid-19 gave scientists an opening to better understand how brain disorders arise

Health Tech By Katie Palmer

A new crop of medical devices are trying to hack the vagus nerve to treat disease

Biotech By Adam Feuerstein

FDA wants more data on promising ALS drug, frustrating patients seeking faster access

Health By Mario Aguilar

Akili’s therapeutic video game will be tested as a treatment for Covid ‘brain fog’

Health By Elizabeth Cooney

1 in 3 Covid-19 patients are diagnosed with a neuropsychiatric condition in the next six months, large study finds

First Opinion Podcast By Patrick Skerrett

Jason Karlawish and an Alzheimer’s caregiver on dementia’s ripple effect

Pharmalot By Ed Silverman

With time running out, an ALS patient fights with Biogen over expanded access to its drug

Pharmalot By Ed Silverman

Medicare spending on neurology drugs jumped, while number of claims barely budged

Biotech By Damian Garde

Ovid sells off its lead drug to double down on neuro research

Health By Rebecca Sohn

With chronic migraines, she avoided light for 18 months — and developed a condition from centuries past

Biotech By Adam Feuerstein

Brainstorm’s cell therapy for ALS lacks convincing clinical data for FDA submission, agency concludes

In the Lab By Nicholas St. Fleur

STAT+ Conversations: A conversation on race, science, and advocacy with Black in Neuro founder Angeline Dukes

In the Lab By Theresa Gaffney

Studying brain organoids with a Neanderthal gene, scientists unlock clues to modern human evolution

Health Tech By Mario Aguilar

Apple Watch can help track Parkinson’s disease symptoms, research shows

Biotech By Adam Feuerstein and Damian Garde

Most Read

6 ways the FDA’s approval of Aduhelm does more harm than good

Poll: Most Americans believe new Alzheimer’s drug is effective, but many are concerned with FDA process

Long after the fire of a Covid-19 infection, mental and neurological effects can still smolder

A crucial, overlooked question on the new Alzheimer’s drug: When should patients stop taking it?

When even soft noises feel like a knife to the eardrums

‘I’m just winging it’: Faced with confusing data on the new Alzheimer’s drug, doctors scramble to advise their patients

Muhammad Ali and Parkinson’s disease: Was boxing to blame?

The maddening saga of how an Alzheimer’s ‘cabal’ thwarted progress toward a cure for decades

All Coverage

Expert panel votes unanimously that Biogen Alzheimer’s drug doesn’t offer patient benefits

‘Aduhelm left room’: Lilly CEO eyes competition with Biogen Alzheimer’s drug

Poll: Most neurologists and primary care doctors disagree with FDA’s approval of Alzheimer’s drug

Will FDA quickly review a Lilly drug to alleviate cost concerns for Alzheimer’s treatments?

‘A litany of flaws’: Advocacy group urges HHS to boot FDA officials over Alzheimer’s drug approval

Advocates blast the FDA for not moving as fast on ALS as on Alzheimer’s

What’s next for the new Alzheimer’s drug? Lots of thorny issues ahead

The parents hoped an existing drug might keep their kids from having seizures. Then they saw the price

Biogen’s Alzheimer’s drug may only be cost effective at $2,500 a year

Biogen to expand access to its ALS drug, but move may come too late for some patients

Covid-19 gave scientists an opening to better understand how brain disorders arise

A new crop of medical devices are trying to hack the vagus nerve to treat disease

FDA wants more data on promising ALS drug, frustrating patients seeking faster access

Akili’s therapeutic video game will be tested as a treatment for Covid ‘brain fog’

1 in 3 Covid-19 patients are diagnosed with a neuropsychiatric condition in the next six months, large study finds

Jason Karlawish and an Alzheimer’s caregiver on dementia’s ripple effect

With time running out, an ALS patient fights with Biogen over expanded access to its drug

Medicare spending on neurology drugs jumped, while number of claims barely budged

Ovid sells off its lead drug to double down on neuro research

With chronic migraines, she avoided light for 18 months — and developed a condition from centuries past

Brainstorm’s cell therapy for ALS lacks convincing clinical data for FDA submission, agency concludes

STAT+ Conversations: A conversation on race, science, and advocacy with Black in Neuro founder Angeline Dukes

Studying brain organoids with a Neanderthal gene, scientists unlock clues to modern human evolution

Apple Watch can help track Parkinson’s disease symptoms, research shows

FDA delays approval decision for Biogen’s Alzheimer’s treatment